En résumé

Double compétence scientifique/business: bac+5 en biologie complété par le MS Management des Entreprises de Biotech (Grenoble Ecole de Management).

Mes compétences :
Business development


  • Virbac - Scientific Competitive Intelligence

    Carros 2013 - maintenant Founded in 1968 in Carros close to Nice by veterinarian Pierre-Richard Dick, Virbac is dedicated exclusively to animal health. With a turnover of €695 million in 2012, the company ranks today as the 8th largest animal health company worldwide. Its wide range of vaccines and medicines are used in the prevention and treatment of the main pathologies for both companion and food-producing animals.

    Over the last forty years Virbac has become the world's first independent animal health company dedicated to animal health and a recognised expert in the sector, offering products and services that combine quality, effectiveness and convenience for care providers (veterinarians and animal owners).

    Present in more than 100 countries the company has more than 4,100 employees. Quoted on the Paris Stock Exchange since 1985 Virbac has remained a family company, not only as regards its shareholding but also through its management principles, its culture and its company values.

    International presence has been an integral part of Virbac's strategy since the very beginning. Starting in 1978, group expansion abroad speeded up progressively in the 1980s and then in the 1990s. Today Virbac is present in all 5 continents, with around 87% of its sales made outside of France.
  • Creapharm - Business Development Manager

    LE HAILLAN 2010 - 2011
  • ERYtech pharma - Business Development Unit

    LYON 2008 - 2010 ERYtech Pharma (Lyon, Philadelphia) is a specialty pharma developing new high value medicinal products for unmet clinical needs in the fields of oncology and hematology.
    Its business model consists both of developing and selling new innovative medicinal products and of partnering with pharma/biotech companies.
    ERYtech Pharma’s patented technology and platform offer large possibilities to create new products and IP on an industrial scale.
    ERYtech Pharma has built in less than five years a strong pipeline with very ambitious programs.
    The ambition of the company is to become a world leader in the pharmaceutical industry using red blood cells.
  • Protein'eXpert - Chargé d'études Marketing

    2007 - 2007 Funded in 2000 in Grenoble, France, Protein’eXpert has been offering contract research services focusing on the engineering and development of valuable and complex recombinant proteins.
    Protein’eXpert has then extended its range of services to the biomanufacturing of therapeutic protein products for early clinical trials via its integrated subsidiary PX’Pharma in 2004. PX’Pharma has been providing dedicated contract services for process development & scale-up optimization, preclinical and clinical cGMP production.

    In 2007, a new subsidiary named PX’Monoclonals has been created to propose services ranging from the generation of high affinity murine monoclonal antibodies to the development of chimeric and humanized antibodies for therapeutic use.

    On September 2008, Protein’eXpert becomes PX’Therapeutics.
  • CNRS - Trainee

    Paris 2006 - 2006 INRA Pharmacologie Toxicologie (Saint Martin du Touch)

    Feb - May
  • INRA - Trainee

    Paris 2005 - 2005 CNRS LIPM (Toulouse)

    Jan - Sept



Annuaire des membres :